Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Die Diabetologie
Erschienen in: Die Diabetologie 5/2023

27.04.2023 | Typ-2-Diabetes | DDG Praxisempfehlungen

Therapie des Typ-2-Diabetes

verfasst von: Prof. Dr. med. Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel

Erschienen in: Die Diabetologie | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://​www.​deutsche-diabetes-gesellschaft.​de/​behandlung/​leitlinien) befinden sich alle PDF zum kostenlosen Download. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Dziopa K, Asselbergs FW, Gratton J et al (2022) Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings. Diabetologia 65:644–656PubMedPubMedCentral
3.
Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome. Circulation 120:1640–1645PubMed
4.
Elwyn G, Vermunt NPCA (2020) Goal-based shared decision-making: developing an integrated model. J Patient Exp 7:688–696PubMed
5.
Wang R, Song Y, Yan Y et al (2016) Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: a meta-analysis. Atherosclerosis 254:193–199PubMed
6.
Parhofer KG, Birkenfeld AL, Krone W et al (2022) Lipidtherapie bei Patienten mit Diabetes mellitus. Diabetologie 17(Suppl. 02):S316–S322
7.
Zeiner Z, Catapano AL, de Backer G et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769–1818
8.
Heinemann L, Kaiser P, Freckmann G et al (2018) HbA1c-Messung in Deutschland: Ist die Qualität ausreichend für Verlaufskontrolle und Diagnose? Diabetologie 13:46–53
9.
Landgraf R, Nauck M, Freckmann G et al (2018) Fallstricke bei der Diabetesdiagnostik: Wird zu lax mit Laborwerten umgegangen? Dtsch Med Wochenschr 143:1549–1555PubMed
10.
Landgraf R, Heinemann L, Schleicher E et al (2022) Definition, Klassifikation und Diagnostik des Diabetes mellitus. Update 2022. Diabetologie 17(Suppl. 02):S98–S110
11.
Landgraf R (2021) HbA1c in der Diabetesdiagnostik. Der Goldstandard? Diabetes Aktuell 19:22–29
12.
Ahlqvist E, Storm P, Käräjämäki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6:361–369PubMed
13.
Zaharia OP, Strassburger K, Strom A, German Diabetes Study Group et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5‑year follow-up study. Lancet Diabetes Endocrinol 7:684–694PubMed
14.
Dennis JM, Shields BM, Henley WE et al (2019) Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 7:442–451PubMedPubMedCentral
15.
Han H, Cao Y, Feng C et al (2022) Association of a healthy lifestyle with all-cause and cause-specific mortality among individuals with type 2 diabetes: a prospective study in UK Biobank. Diabetes Care 45:319–329PubMed
16.
Zhang Y, Pan XF, Chen J et al (2020) Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Diabetologia 63:21–33PubMed
17.
18.
19.
Forouhi NG, Misra A, Mohan V et al (2018) Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ 361:k2234PubMedPubMedCentral
20.
Serra-Majem L, Román-Viñas B, Sanchez-Villegas A et al (2019) Benefits of the Mediterranean diet: epidemiological and molecular aspects. Mol Aspects Med 67:1–55PubMed
21.
Taylor R, Al-Mrabeh A, Sattar N (2019) Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol 7:726–736PubMed
22.
Evert AB, Dennison M, Gardner CD et al (2019) Nutrition therapy for adults with Diabetes or prediabetes: a consensus report. Diabetes Care 42:731–754PubMedPubMedCentral
23.
Hauner H (2021) Evidenz in der Ernährungstherapie des Diabetes mellitus. Diabetologe 17:687–696
24.
Chester B, Babu JR, Greene MW et al (2019) The effects of popular diets on type 2 diabetes management. Diabetes Metab Res Rev 35:e3188PubMed
25.
Naude CE, Brand A, Schoonees A et al (2022) Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk (review). Cochrane Database Syst Rev 1:CD13334PubMed
26.
Patikorn C, Roubal K, Sajesh KV et al (2021) Intermittent fasting and obesity-related health outcomes. An umbrella review of meta-analyses of randomized clinical trials. JAMA Netw Open 4:e2139558PubMedPubMedCentral
27.
Thackrey E, Chen J, Martino CR et al (2022) The effects of diet on weight and metabolic outcomes in patients with double diabetes: A systematic review. Nutrition 94:111536PubMed
28.
Kempf K, Altpeter B, Berger J et al (2017) Efficacy of the telemedical lifestyle intervention program TeLiPro in advanced stages of type 2 diabetes: A randomized controlled trial. Diabetes Care 40:863–871PubMed
29.
Lean MEJ, Leslie WS, Barnes AC et al (2019) Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2‑year results of the DiRECT open-label, cluster-randomized trial. Lancet Diabetes Endocrinol 7:344–355PubMed
30.
Adipositas – Prävention und Therapie. AWMF-Register Nr. 050-001
31.
Yang D, Yang Y, Li Y et al (2019) Physical exercise as therapy for type 2 diabetes mellitus: from mechanism to orientation. Ann Nutr Metab 74:313–321PubMed
32.
Tarp J, Støle AP, Blond K et al (2019) Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and metaanalysis. Diabetologia 62:1129–1142PubMedPubMedCentral
33.
Liu Y, Ye W, Chen Q et al (2019) Resistance exercise intensity is correlated with attenuation of HbA1c and insulin in patients with type 2 diabetes: A systematic review and meta-analysis. Int J Environ Res Public Health 16:140PubMedPubMedCentral
34.
Esefeld K, Kress S, Behrens M et al (2021) Diabetes, Sport und Bewegung. Diabetologe 16(Suppl. 02):S299–S307
35.
Piercy KL, Richard P, Troiano RP et al (2018) The physical activity guidelines for Americans. JAMA 320:2020–2028PubMedPubMedCentral
36.
Jabardo-Camprubí G, Donat-Roca R, Sitjà-Rabert M et al (2020) Drop-out ratio between moderate to high-intensity physical exercise treatment by patients with, or at risk of, type 2 diabetes mellitus: A systematic review and meta-analysis. Physiol Behav 215:112786PubMed
37.
Villafranca Cartagena M, Tort-Nasarre G, Rubinat Arnaldo E (2021) Barriers and Facilitators for physical activity in adults with type 2 diabetes mellitus: a scoping review. Int J Environ Res Public Health 18:5359
38.
MacDonald CS, Ried-Larsen M, Soleimani J et al (2021) A systematic review of adherence to physical activity interventions in individuals with type 2 diabetes. Diabetes Metab Res Rev 37:e3444PubMed
39.
Thomsen S, Kristensen GDW, Jensen NWH et al (2021) Maintaining changes in physical activity among type 2 diabetics—A systematic review of rehabilitation interventions. Scand J Med Sci Sports 31:1582–1591PubMed
40.
Pan A, Wang Y, Talaei M et al (2015) Relation of active, passive, and quitting smoking with incident diabetes: a meta-analysis and systematic review. Lancet Diabetes Endocrinol 3:958–996PubMedPubMedCentral
41.
Kar D, Gillies C, Nath M et al (2019) Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 56:839–850PubMedPubMedCentral
42.
Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung. S3-Leitlinie Langversion AWMF-Register Nr. 076-006
43.
44.
Concato J, Corrigan-Curay J (2022) Real-world evidence—Where are we now? N Engl J Med 386:1680–1682PubMed
45.
Fleming GA, Petrie JR, Bergenstal RM et al (2020) Diabetes digital app technology: Benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care 43:250–260PubMed
46.
Khunti K, Gomes MB, Pocock S et al (2018) Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab 20:427–437PubMed
47.
Matthews DR, Paldánius PM, Proot P, VERIFY study group et al (2019) Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5‑year, multicentre, randomized, double-blind trial. Lancet 394:1519–1529PubMed
48.
Meier JJ (2021) Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol 12:645617
49.
Gallwitz B, Giorgino F (2021) Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol 12:645507
50.
Gough SC, Bode B, Woo V et al (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2:885–893PubMed
51.
Diamant M, Nauck MA, Shaginian R et al (2014) Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 37:2763–2773PubMed
52.
Ahmann A, Rodbard HW, Rosenstock J et al (2015) Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo controlled trial. Diabetes Obes Metab 17:1056–1064PubMedPubMedCentral
53.
Montvida O, Klein K, Kumar S et al (2017) Addition of or switch to insulin therapy in people treated with glucagon-like peptide‑1 receptor agonists: A real-world study in 66 583 patients. Diabetes Obes Metab 19:108–117PubMed
54.
Billings LK, Doshi A, Gouet D et al (2018) Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The DUAL VII randomized clinical trial. Diabetes Care 41:1009–1016PubMed
55.
Gomez-Peralta F, Al-Ozairi E, Jude EB et al (2021) Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide‑1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes Obes Metab 23:1445–1452PubMedPubMedCentral
56.
Averna M, Catapano AL (2022) One year after the ESC/EAS guidelines on cholesterol control. What’s the new evidence? What’s missing? Eur J Intern Med 95:1–4PubMed
57.
58.
American Diabetes Association (2021) Cardiovascular disease and risk management: Standards of medical care in diabetes—2021. Diabetes Care 44(Suppl. 01):S125–S150
59.
The SPRINT Research Group (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116PubMedCentral
60.
61.
Kidney Disease: Improving Global Outcomes Blood Pressure Work Group (2021) KDIGO 2021 clinical practice guideline for management of blood pressure in chronic kidney disease. Kidney Int 99:S1–S87
62.
Merker L, Bautsch BW, Ebert T et al (2022) Nephropathie bei Diabetes. Diabetologie 17(Suppl. 02):S327–S331
63.
American Diabetes Association Professional Practice Committee (2022) Chronic kidney disease and risk management: standards of medical care in diabetes—2022. Diabetes Care 45((Suppl. 01):S175–S184
64.
Lawall H, Huppert P, Rümenapf G et al (2015) Periphere arterielle Verschlusskrankheit (PAVK), Diagnostik, Therapie und Nachsorge. AWMF-Register Nr. 065-003 (gültig bis 29.11.2020, in Überarbeitung)
65.
Ziegler D, Tesfaye S, Spallone V et al (2022) Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Res Clin Pract 186:109063PubMed
66.
67.
68.
Roeb E, Steffen HM, Bantel H et al (2015) S2k-Leitlinie: Nicht-alkoholische Fettlebererkrankungen (AWMF-Register Nr. 021-025)
69.
70.
71.
The Look AHEAD Research Group (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145–154PubMedCentral
72.
Unick JL, Gaussoin SA, Hill JO et al (2017) Objectively assessed physical activity and weight loss maintenance among individuals enrolled in a lifestyle intervention. Obesity (Silver Spring) 25:1903–1909PubMed
73.
The Look AHEAD Research Group (2016) Association of the magnitude of weight loss and changes in physical fitness with longterm cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol 4:913–921
74.
Gregg EW, Lin J, Bardenheier B et al (2018) Impact of intensive lifestyle intervention on disability-free life expectancy: the look AHEAD study. Diabetes Care 41:1040–1048PubMedPubMedCentral
75.
Chao AM, Wadden TA, Berkowitz RI, Look AHEAD Research Group et al (2020) Weight change 2 years after termination of the intensive lifestyle intervention in the Look AHEAD Study. Obesity 28:893–890PubMed
76.
Liu Y, Ye W, Chen Q et al (2019) Resistance exercise intensity is correlated with attenuation of HbA1c and insulin in patients with type 2 diabetes: A systematic review and meta-analysis. Int J Environ Res Public Health 16:E140
77.
Thomsen S, Westergaard Kristensen GD, Weigelt N et al (2021) Maintaining changes in physical activity among type 2 diabetics—A systematic review of rehabilitation interventions. Scand J Med Sci Sports 31:1582–1591PubMed
78.
Jansson AK, Chan LX, Lubans DR et al (2022) Effect of resistance training on HbA1c in adults with type 2 diabetes mellitus and the moderating effect of changes in muscular strength: a systematic review and meta-analysis. BMJ Open Diab Res Care 10:e2595PubMedPubMedCentral
79.
Kanaley JA, Colberg SR, Corcoran MH et al (2022) Exercise/physical activity in individuals with type 2 diabetes: a consensus statement from the American College of Sports Medicine. Med Sci Sports Exerc 54:353–368PubMedPubMedCentral
80.
Balducci S, Haxhi J, Sacchetti M et al (2022) Relationships of changes in physical activity and sedentary behavior with changes in physical fitness and cardiometabolic risk profile in individuals with type 2 diabetes: the Italian diabetes and exercise study 2 (IDES_2). Diabetes Care 45:213–221PubMed
81.
82.
Lazarus B, Wu A, Shin JI et al (2018) Association of metformin use with risk of lactic acidosis across the range of kidney function. A community-based cohort study. JAMA Intern Med 178:903–910PubMedPubMedCentral
83.
Griffin SJ, Leaver JK, Irving GJ et al (2017) Impact of metformin on cardiovascular disease: a meta-analysis of randomized trails among people with type 2 diabetes. Diabetologia 60:1620–1629PubMedPubMedCentral
84.
Palmer SC, Mavridis D, Nicolucci A et al (2016) Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA 316:313–324PubMed
85.
Madsen KS, Kähler P, Kähler LKA et al (2019) Metformin and second- or third generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 4:CD12368PubMed
86.
Sattar N, McGuire DK (2021) Prevention of CV outcomes in antihyperglycemic drug-naive patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin. Eur Heart J 42:2574–2576PubMed
87.
Rena G, Mordi IR, Lang CC (2020) Metformin: still the sweet spot for CV protection in diabetes? Curr Opin Pharmacol 54:202–208PubMed
88.
Gonzalez-Gonzalez JG, Solis RC, Gonzalez-Colmenero AD et al (2022) Effect of metformin on microvascular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 186:109821PubMedCentral
89.
Lee CG, Heckman-Stoddard B, Dabelea D et al (2021) Effect of Metformin and lifestyle interventions on mortality in the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care 44:2775–2782PubMedPubMedCentral
90.
Mallik R, Chowdhury TA (2018) Metformin in cancer. Diabetes Res Clin Pract 143:409–419PubMed
91.
Thakur S, Daley B, Klubo-Gwiezdzinska J (2019) The role of the antidiabetic drug metformin in the treatment of endocrine tumors. J Mol Endocrinol 63:R17–R35PubMedPubMedCentral
92.
De A, Kuppusamy G (2020) Metformin in breast cancer: preclinical and clinical evidence. Curr Probl Cancer 44:100488PubMed
93.
Rahmani J, Manzari N, Thompson J et al (2020) The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials. Clin Transl Oncol 22:37–49PubMed
94.
Fong W, To KKW (2020) Drug repurposing to overcome resistance to various therapies for colorectal cancer. Cell Mol Life Sci 76:3383–3406
95.
Aljofan M, Riethmacher D (2019) Anticancer activity of metformin: a systematic review of the literature. Future Sci OA 5:FSO410PubMedPubMedCentral
96.
Feng Z, Zhou X, Liu N et al (2019) Metformin use and prostate cancer risk: A meta-analysis of cohort studies. Medicine (Baltimore) 98:e14955PubMed
97.
Park YMM, Bookwalter DB, O’Brien KM et al (2021) A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Ann Oncol 32:351–359PubMed
98.
Lv Z, Guo Y (2020) Metformin and its benefits for various diseases. Front Endocrinol 11:191
99.
Prodromidou A, Lekka S, Fotiou A et al (2021) The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer: A systematic review and meta-analysis of randomized controlled trials. J Gynecol Obstet Hum Reprod 50:102164PubMed
100.
Wang Q (2022) Shi M Effect of metformin use on the risk and prognosis of colorectal cancer in diabetes mellitus: a meta-analysis. Anticancer Drugs 33:191–199PubMed
101.
Wensink MJ, Lu Y, Tian L (2022) Preconception antidiabetic drugs in men and birth defects in offspring. A nationwide cohort study. Ann Intern Med 175:665–673PubMedPubMedCentral
102.
Khunti K, Knighton P, Zaccardi F et al (2021) Prescription of glucose lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol 9:293–303PubMedPubMedCentral
103.
Steenblock C, Schwarz PEH, Ludwig B et al (2021) COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol 9:786–798PubMedPubMedCentral
104.
Bornstein SR, Rubino F, Khunti K et al (2020) Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 8:546–550PubMedPubMedCentral
105.
Wargny M, Potier L, Gourdy P et al (2021) Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia 64:778–794PubMedPubMedCentral
106.
Kow CS, Hasan SS (2021) Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis. J Med Virol 93:695–697PubMed
107.
Lim S, Bae JH, Kwon H‑S, Nauck MA (2021) COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 17:11–30PubMed
108.
Oshima M, Jun M, Ohkuma T et al (2019) The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. Diabetologia 62:1988–1997PubMedPubMedCentral
109.
The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
110.
Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of linagliptin vs. glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA randomized clinical trial. JAMA 322:1155–1116PubMedPubMedCentral
111.
Rados DV, Pinto LC, Remonti LR et al (2016) The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 13:e1001992
112.
Azoulay L, Suissa S (2017) Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care 40:706–714PubMed
113.
Bain S, Druyts E, Balijepalli C et al (2017) Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab 19:329–335PubMed
114.
Zhuang XD, He X, Yang DY et al (2018) Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166 371 participants from170 randomized controlled trials. Cardiovasc Diabetol 17:79PubMedPubMedCentral
115.
Powell WR, Christiansen CL, Miller DR (2018) Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments. Diabetes Ther 9:1431–1440PubMedPubMedCentral
116.
Simpson SH, Lee J, Choi S et al (2015) Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 3:43–51PubMed
117.
Hemmingsen B, Schroll JB, Lund SS et al (2013) Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 4:CD9008
118.
Hemmingsen B, Schroll JB, Jorn Wetterslev J et al (2014) Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2:E162–E175PubMedPubMedCentral
119.
Vaccaro O, Masulli M, Nicolucci M et al (2017) Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomized, multicenter trial. Lancet Diabetes Endocrinol 5:887–897PubMed
120.
Ogundipe O, Mazidi M, Chin KL et al (2021) Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase‑4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. Acta Diabetol 58:39–46PubMed
121.
Khan MS, Solomon N, DeVore AD (2022) Clinical outcomes with metformin and sulfonylurea therapies among patients with heart failure and diabetes. JACC Heart Fail 10:198–210PubMed
122.
Chen K, Kang D, Yu M et al (2018) Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase‑4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials. Diabetes Obes Metab 20:1029–1033PubMed
123.
Patorno E, Schneeweiss S, Gopalakrishnan C et al (2019) Using real world data to predict findings of an ongoing phase IV cardiovascular outcome trial: Cardiovascular safety of linagliptin versus glimepiride. Diabetes Care 42:2204–2210PubMedPubMedCentral
124.
Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326PubMed
125.
White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335PubMed
126.
Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242PubMed
127.
Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA Randomized Clinical Trial. JAMA 321:69–79PubMed
128.
Perkovic V, Toto R, Cooper ME et al (2020) Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial. Diabetes Care 43:1803–1812PubMedPubMedCentral
129.
Monami M, Ahrén B, Dicembrini I et al (2013) Dipeptidyl peptidase‑4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 15:112–120PubMed
130.
Xu S, Zhang X, Tang L et al (2017) Cardiovascular effects of dipeptidylpeptidase‑4 inhibitor in diabetic patients with and without established cardiovascular disease: A meta-analysis and systematic review. Postgrad Med 129:205–215PubMed
131.
Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA 319:1580–1591PubMedPubMedCentral
132.
Ling J, Cheng P, Ge L et al (2019) The efficacy and safety of dipeptidyl peptidase‑4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetol 56:249–272PubMed
133.
134.
Guo WQ, Li L, Su Q et al (2017) Effect of dipeptidylpeptidase‑4 inhibitors on heart failure: A network meta-analysis. Value Health 20:1427–1430PubMed
135.
Nauck MA, Meier JJ, Cavender MA et al (2017) Cardiovascular actions and clinical outcomes with glucagon-like peptide‑1 receptor agonists and dipeptidyl peptidase‑4 inhibitors. Circulation 136:849–870PubMed
136.
Sinha B, Ghosal S (2019) Meta-analyses of the effects of DPP‑4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 150:8–16PubMed
137.
Xie Y, Bowe B, Gibson AK et al (2020) Comparative effectiveness of SGLT2 inhibitors, GLP‑1 receptor agonists, DPP‑4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care 43:2859–2869PubMed
138.
Kanie T, Mizuno A, Takaoka Y et al (2021) Dipeptidyl peptidase‑4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter‑2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev 10:CD13650PubMed
139.
Dougherty J, Guirguis E, Thornby KA et al (2021) A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease. Ann Pharmacother 55:65–79PubMed
140.
Kumar J, Memon RS, Shahid I et al (2021) Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. Dig Liver Dis 53:44–51PubMed
141.
Roeb E, Canbay A, Bantel H et al (2022) Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). April 2022 – AWMF-Registernummer: 021-025
142.
Koufakis T, Mustafa OG, Zebekakis P et al (2020) Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close. Diabet Med 37:1418–1426PubMed
143.
Du H, Wang DW, Chen C (2020) The potential effects of DPP‑4 inhibitors on cardiovascular system in COVID-19 patients. J Cell Mol Med 24:10274–10278PubMedPubMedCentral
144.
Bonora BM, Avogaro A, Fadini GP (2021) Disentangling conflicting evidence on DPP‑4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. J Endocrinol Invest 44:1379–1386PubMedPubMedCentral
145.
Yang Y, Cai Z, Zhang J (2021) DPP‑4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis. PLoS ONE 16:e251916PubMedPubMedCentral
146.
Tkáč I, Raz I (2017) Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 40:284–286PubMed
147.
Pinto LC, Rados DV, Barkann SS et al (2018) Dipeptidyl peptidase‑4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis. Sci Rep 8:782PubMedPubMedCentral
148.
Tasanen K, Varpuluoma O, Nishie W (2019) Dipeptidyl peptidase‑4 inhibitor-associated bullous pemphigoid. Front Immunol 10:1238PubMedPubMedCentral
149.
Overbeek JA, Bakker M, van der Heijden AAWA et al (2018) Risk of dipeptidyl peptidase‑4 (DPP-4) inhibitors on site specific cancer: A systematic review and meta-analysis. Diabetes Metab Res Rev 34:e3004PubMed
150.
Dicembrini I, Montereggi C, Nreu B et al (2020) Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase‑4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 159:107981PubMed
151.
152.
Li G, Crowley MJ, Tang H et al (2019) Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease among patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetes Care 42:e119–e121PubMedPubMedCentral
153.
Radel JA, Pender DN, Shah SA (2019) Dipeptidyl peptidase‑4 inhibitors and inflammatory bowel disease risk: a meta-analysis. Ann Pharmacother 53:697–704PubMed
154.
Storgaard H, Gluud LL, Bennett C et al (2016) Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS ONE 11:e166125PubMedPubMedCentral
155.
Monami M, Liistro F, Scatena A et al (2018) Short and medium-term efficacy of sodium glucose co-transporter‑2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 20:1213–1222PubMed
156.
Usman MS, Siddiqi TJ, Memon MM et al (2018) Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol 25:495–502PubMed
157.
Mishriky BM, Tanenberg RJ, Sewell KA et al (2018) Comparing SGLT‑2 inhibitors to DPP‑4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab 44:112–120PubMed
158.
Seidu S, Kunutsor SK, Cos X et al (2018) SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Prim Care Diabetes 12:265–283PubMed
159.
Rådholm K, Wu JH, Wong MG et al (2018) Effects of sodium-glucose cotransporter‑2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes—A systematic review. Diabetes Res Clin Pract 140:118–128PubMed
160.
Aronson R, Frias J, Goldman A et al (2018) Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab 20:1453–1460PubMedPubMedCentral
161.
Hollander P, Hill J, Johnson J et al (2019) Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on Metformin. Curr Med Res Opin 35:1335–1343PubMed
162.
Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39PubMed
163.
Zaman M, Memon RS, Amjad A et al (2020) Effect of ertugliflozin on glycemic levels, blood pressure and body weight of patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes Metab Disord 19:1873–1878PubMedPubMedCentral
164.
Tsapas A, Karagiannis T, Kakotrichi P et al (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab 23:2116–2124PubMed
165.
Täger T, Atar D, Agewall S et al (2021) Comparative efficacy of sodium-glucose cotransporter‑2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Fail Rev 26:1421–1435PubMed
166.
Liu L, Shi FH, Xu H et al (2022) Efficacy and safety of ertugliflozin in type 2 diabetes: A systematic review and meta-analysis. Front Pharmacol 12:752440PubMedPubMedCentral
167.
Duan XY, Liu SY, Yin DG (2021) Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials. Medicine (Baltimore) 100:e26431PubMed
168.
Braunwald E (2022) Gliflozins in the management of cardiovascular disease. N Engl J Med 386:2024–2034PubMed
169.
Puckrin R, Saltiel MP, Reynier P et al (2018) SGLT‑2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55:503–514PubMed
170.
Lega IC, Bronskill SE, Campitelli MA et al (2019) Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes Obes Metab 21:2394–2404PubMed
171.
Dave CV, Schneeweiss S, Patorno E (2019) Comparative risk of genital infections associated with sodium glucose co-transporter‑2 inhibitors. Diabetes Obes Metab 21:434–438PubMed
172.
McGovern AP, Hogg M, Shields BM et al (2020) Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diab Res Care 8:e1238PubMedPubMedCentral
173.
Engelhardt K, Ferguson M, Rosselli JL (2021) Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors. Ann Pharmacother 55:543–548PubMed
174.
Yang JY, Wang T, Pate V et al (2020) Real-world evidence on sodium-glucose cotransporter‑2 inhibitor use and risk of Fournier’s gangrene. BMJ Open Diab Res Care 8:e985PubMedPubMedCentral
175.
Silverii GA, Dicembrini I, Monami M et al (2020) Fournier’s gangrene and sodium-glucose co-transporter‑2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 22:272–275PubMed
176.
Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657PubMed
177.
Huang CY, Lee JK (2020) Sodium-glucose co-transporter‑2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 Individuals. Diabetes Obes Metab 22:2348–2355PubMed
178.
Bai Y, Jin J, Zhou W et al (2021) The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 31:1365–1374PubMed
179.
Paul SK, Bhatt DL, Montvida O (2021) The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type‑2 inhibitors: real-world study. Eur Heart J 42:1728–1738PubMed
180.
Ruanpeng D, Ungprasert P, Sangtian J et al (2017) Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes Metab Res Rev 33:e2903
181.
Tang HL, Li DD, Zhang JJ et al (2016) Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 18:1199–1206PubMed
182.
Li X, Li T, Cheng Y et al (2019) Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis. Diabetes Metab Res Rev 35:e3170PubMed
183.
Hidayat K, Du X, Shi BM (2019) Risk of fracture with dipeptidyl peptidase‑4 inhibitors, glucagon-like peptide‑1 receptor agonists, or sodium-glucose cotransporter‑2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporos Int 30:1923–1940PubMed
184.
Zhuo M, Hawley CE, Paik JM et al (2021) Association of sodium-glucose cotransporter‑2 inhibitors with fracture risk in older adults with type 2 diabetes. JAMA Netw Open 4:e2130762PubMedPubMedCentral
185.
Fralick M, Schneeweiss S, Patorno E (2017) Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 376:2300–2303PubMed
186.
Monami M, Nreu B, Zannoni S et al (2017) Effects of SGLT2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Res Clin Pract 130:53–60PubMed
187.
Fadini GP, Bonora BM, Avogaro A (2017) SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia 60:1385–1389PubMed
188.
Liu J, Li L, Li S et al (2020) Sodium-glucose co-transporter‑2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 22:1619–1627PubMed
189.
Lin DS, Lee JK, Chen WJ (2021) Clinical adverse events associated with sodium–glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J Clin Endocrinol Metab 106:2133–2145PubMed
190.
Thiruvenkatarajan V, Meyer EJ, Nanjappa N et al (2019) Perioperative diabetic ketoacidosis associated with sodium-glucose cotransporter‑2 inhibitors: a systematic review. Br J Anaesth 123:27–36PubMed
191.
Milder DA, Milder TY, Kam PCA (2018) Sodium-glucose co-transporter type‑2 inhibitors: pharmacology and perioperative considerations. Anaesthesia 73:1008–1018PubMed
192.
Donnan K, Segar L (2019) SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol 846:23–29PubMedPubMedCentral
193.
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357PubMed
194.
Mosenzon O, Wiviott SD, Cahn A et al (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7:606–617PubMed
195.
Furtado RHM, Bonaca MP, Raz I (2019) Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and Previous Myocardial Infarction. Circulation 139:2516–2527PubMed
196.
Kato ET, Silverman MG, Mosenzon O et al (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139:2528–2536PubMed
197.
McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008PubMed
198.
Nassif ME, Windsor SL, Borlaug BA et al (2021) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 27:1954–1960PubMedPubMedCentral
199.
Wheeler DC, Stefánsson BV, Jongs N et al (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:22–31PubMed
200.
Waijer SW, Vart P, Cherney DZI et al (2022) Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia 65:1085–1097PubMedPubMedCentral
201.
Kawai Y, Uneda K, Yamada T et al (2022) Comparison of effects of SGLT‑2 inhibitors and GLP‑1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis. Diabetes Res Clin Pract 183:109146PubMed
202.
Neuen BL, Young T, Heerspink HJL (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7:845–854PubMed
203.
Karagiannis T, Tsapas A, Athanasiadou E et al (2021) GLP‑1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 174:108737PubMed
204.
Bae JH, Park EG, Kim S et al (2021) Comparative renal effects of dipeptidyl peptidase‑4 inhibitors and sodium-glucose cotransporter 2 inhibitors on individual outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis. Endocrinol Metab (Seoul) 36:388–400PubMed
205.
Palmer SC, Tendal B, Mustafa RA et al (2021) Sodium-glucose cotransporter protein‑2 (SGLT-2) inhibitors and glucagon-like peptide‑1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 372:m4573PubMedPubMedCentral
206.
Kaze AD, Zhuo M, Seoyoung C, Kim SC et al (2022) Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol 21:47PubMedPubMedCentral
207.
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128PubMed
208.
Inzucchi SE, Khunti K, Fitchett DH et al (2020) Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial. J Clin Endocrinol Metab 105:3025–3035PubMedPubMedCentral
209.
McGuire DK, Zinman B, Inzucchi SE et al (2020) Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol 8:949–959PubMed
210.
Wanner C, Inzucchi SE, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334PubMed
211.
Cherney DZI, Zinman B, Inzucchi SE et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: An exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5:610–621PubMed
212.
Verma S, Mazer CD, Fitchett D et al (2018) Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: sub-analysis of the EMPA-REG OUTCOME® randomized trial. Diabetologia 61:1712–1723PubMedPubMedCentral
213.
Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424PubMed
214.
Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461PubMed
215.
Packer M, Butler J, Zannad F et al (2021) Empagliflozin and major renal outcomes in heart failure. N Engl J Med 385:1531–1533PubMed
216.
Butler J, Milton Packer M, Filippatos G et al (2022) Effect of Empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 43:416–426PubMed
217.
218.
Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425–1435PubMed
219.
Rosenstock J, Frias J, Páll D et al (2018) Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 20:520–529PubMed
220.
Hollander P, Liu J, Hill J et al (2018) Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther 9:193–207PubMed
221.
Cherney DZI, Heerspink HJL, Frederich R et al (2020) Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia 63:1128–1140PubMedPubMedCentral
222.
Cherney DZI, Charbonnel B, Cosentino F (2021) Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial; VERTIS CV Investigators. Diabetologia 64:1256–1267PubMedPubMedCentral
223.
224.
Dagogo-Jack S, Pratley RE, Cherney DZI et al (2021) Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Res Care 9:e2484PubMedPubMedCentral
225.
Zhao LM, Huang JN, Qiu M et al (2021) Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials. Medicine (Baltimore) 100:e27362PubMed
226.
Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306PubMed
227.
Yu J, Li J, Leaver PJ et al (2021) Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial. Cardiovasc Res 118:1103–1114
228.
Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384:117–128PubMed
229.
Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384:129–139PubMed
230.
Avgerinos I, Karagiannis T, Kakotrichi P et al (2022) Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 24:106–114PubMed
231.
Zou CY, Liu XK, Sang YQ et al (2019) Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes. A meta-analysis. Medicine (Baltimore) 98(e18):245
232.
Salah HM, Al’Aref SJ, Khan MS et al (2021) Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. Am Heart J 233:86–91PubMed
233.
Qiu M, Ding L, Zhou H (2021) Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis. Medicine 100:e25121PubMedPubMedCentral
234.
Yamada T, Wakabayashi M, Bhalla A et al (2021) Cardiovascular and renal outcomes with SGLT‑2 inhibitors versus GLP‑1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol 20:14PubMedPubMedCentral
235.
Li CX, Liang S, Gao L et al (2021) Cardiovascular outcomes associated with SGLT‑2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. PLoS ONE 16:e244689PubMedPubMedCentral
236.
Lin FJ, Wang CC, Hsu CN et al (2021) Renoprotective effect of SGLT‑2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study. Cardiovasc Diabetol 20:203PubMedPubMedCentral
237.
Lin DS, Lee JK, Hung CS et al (2021) The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia 64:2676–2686PubMed
238.
Teo YH, Yoong CSY, Syn NL et al (2021) Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 77:1453–1464PubMed
239.
Teo YH, Teo YN, Syn NL et al (2021) Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc 10:e19463PubMedPubMedCentral
240.
Barbarawi M, Al-Abdouh A, Barbarawi O et al (2022) SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev 27:951–960PubMed
241.
Giugliano D, Longo M, Scappaticcio L et al (2021) SGLT‑2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol 20:236PubMedPubMedCentral
242.
Giugliano D, Longo M, Caruso P et al (2021) Sodium-glucose co-transporter‑2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis. Diabetes Obes Metab 23:1672–1676PubMed
243.
Kaze AD, Zhuo M, Kim SC et al (2022) Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol 21:47PubMedPubMedCentral
244.
Sattar N, McLaren J, Kristensen SL et al (2016) SGLT2 Inhibition and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 59:1333–1339PubMedPubMedCentral
245.
Ferrannini E, Mark M, Mayoux E et al (2016) CV Protection in the EMPA-REG OUTCOME Trial: A “thrifty substrate” hypothesis. Diabetes Care 39:1108–1114PubMed
246.
Dutka M, Bobiński R, Ulman-Włodarz I et al (2021) Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure. Heart Fail Rev 26:603–622PubMed
247.
Thomas MC, Cherney DZI (2018) The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61:2098–2210PubMed
248.
Yurista SR, Chong CR, Badimon JJ et al (2021) Therapeutic potenzial of ketone bodies for patients with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 77:1660–1669PubMed
249.
Levin PA, Nguyen H, Wittbrodt ET et al (2017) Glucagon-like peptide‑1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes 10:123–139PubMedPubMedCentral
250.
Nauck MA, Kemmeries G, Holst JJ et al (2011) Rapid tachyphylaxis of the glucagon-like peptide 1‑induced deceleration of gastric emptying in humans. Diabetes 60:1561–1565PubMedPubMedCentral
251.
Meier JJ, Rosenstock J, Hincelin-Mery A et al (2015) Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial. Diabetes Care 38:1263–1273PubMed
252.
Drucker DJ, Buse JB, Taylor K et al (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240–1250PubMed
253.
Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377:1228–1239PubMedPubMedCentral
254.
Fudim M, White J, Pagidipati NJ et al (2019) Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes. Insights from the EXSCEL trial. Circulation 140:1613–1622PubMedPubMedCentral
255.
Bonora BM, Avogaro A, Fadini GP (2019) Effects of exenatide longacting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 56:1051–1060PubMed
256.
Jabbour SA, Frías JP, Ahmed A et al (2020) Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION‑8 study: a multicenter, double-blind, phase 3, randomized controlled trial. Diabetes Care 43:2528–2536PubMedPubMedCentral
257.
Bethel MA, Patel RA, Merrill P et al (2018) Cardiovascular outcomes with glucagon-like peptide‑1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6:105–113PubMed
258.
van der Aart-van der Beek AB, van Raalte DH, Guja C et al (2020) Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials. Diabetes Obes Metab 22:1556–1566PubMedPubMedCentral
259.
Inaishi J, Saisho Y (2022) Exenatide once weekly for management of type 2 diabetes: a review. Clin Pharmacol 14:19–26PubMedPubMedCentral
260.
Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247–2257PubMed
261.
Home P, Blonde L, Kalra S et al (2020) Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. Diabetes Obes Metab 22:2179–2188PubMed
262.
Ferrannini E, Niemoeller E, Dex T et al (2022) Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves β‑cell function in people with type 2 diabetes. Diabetes Obes Metab 24:1159–1165PubMedPubMedCentral
263.
Lundgren JR, Janus C, Jensen SBK et al (2021) Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 384:1719–1730PubMed
264.
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322PubMedPubMedCentral
265.
Verma S, Bhatt DL, Bain SC et al (2018) Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease. Circulation 137:2179–2183PubMed
266.
Marso SP, Nauck MA, Monk Fries T et al (2018) Myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of liraglutide therapy (from the LEADER Trial). Am J Cardiol 121:1467–1470PubMed
267.
Duan CM, Wan TF, Wang Y et al (2019) Cardiovascular outcomes of liraglutide in patients with type 2 diabetes. A systematic review and meta-analysis. Medicine 98:e17860PubMedPubMedCentral
268.
Mann JFE, Ørsted DD, Buse JB (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377:839–848PubMed
269.
Shaman AM, Bain SC, Bakris GL et al (2022) Effect of the glucagon-like peptide‑1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145:575–585PubMed
270.
Heller SR, Geybels MS, Iqbal A et al (2022) A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study. Diabetologia 65:55–64PubMed
271.
Unger J, Allison DC, Kaltoft M et al (2022) Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME). Diabetes Obes Metab 24:204–211PubMed
272.
Kristensen SL, Rørth R, Jhund PS (2019) Cardiovascular, mortality, and kidney outcomes with GLP‑1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776–785PubMed
273.
274.
Pasternak B, Wintzell V, Eliasson B et al (2020) Use of glucagon like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care 43:1326–1335PubMed
275.
Mac Isaac RJ (2020) Dulaglutide and Insulin: How can the AWARD studies help guide clinical practice? Diabetes Ther 11:1627–1638PubMed
276.
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130PubMed
277.
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomized, placebo-controlled trial. Lancet 394:131–138PubMed
278.
Dagenais GR, Rydén L, Leiter LA et al (2020) Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol 19:199PubMedPubMedCentral
279.
Ferrannini G, Gerstein H, Colhoun HM et al (2021) Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J 42:2565–2573PubMed
280.
Mishriky BM, Cummings DM, Powell JR et al (2019) Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 45:102–109PubMed
281.
Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly Semaglutide in adults with overweight or obesity. N Engl J Med 384:989PubMed
282.
Wadden TA, Bailey TS, Billings LK et al (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325:1403–1413PubMed
283.
Rubino D, Abrahamsson N, Davies M et al (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325:1414–1425PubMed
284.
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844PubMed
285.
Leiter LA, Bain SC, Hramiak I et al (2019) Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol 18:73PubMedPubMedCentral
286.
Husain M, Birkenfeld AL, Donsmark M et al (2019) PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381:841–851PubMed
287.
Avgerinos I, Michailidis T, Liakos A et al (2020) Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 22:335–345PubMed
288.
Aroda VR, Bauer R, Christiansen E (2022) Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. Diabetes Obes Metab 24:1338–1350PubMedPubMedCentral
289.
Husain M, Bain SC, Holst AG et al (2020) Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol 19:156PubMedPubMedCentral
290.
Nauck MA, Quast DR (2021) Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6. Front Endocrinol (Lausanne) 12:645566PubMed
291.
Dicembrini I, Nreu B, Scatena A et al (2017) Microvascular effects of glucagon-like peptide‑1 receptor agonists in type 2 diabetes: A meta-analysis of randomized controlled trials. Acta Diabetol 54:933–941PubMed
292.
Mann JFE, Hansen T, Idorn T et al (2020) Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol 8:880–893PubMed
293.
Hammerman A, Moore CM, Aboalhasan E (2022) Usefulness of empagliflozin versus oral semaglutide for prevention of cardiovascular mortality in patients with type 2 diabetes mellitus. Am J Cardiol 170:128–131PubMed
294.
Home PD, Ahrén B, Reusch JEB et al (2017) Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Longterm efficacy with or without rescue therapy. Diabetes Res Clin Pract 131:49–60PubMed
295.
Ahrén B, Carr MC, Murphy K et al (2017) Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. Diabetes Res Clin Pract 126:230–239PubMed
296.
Hernandez AF, Green JB, Janmohamed S et al (2018) Harmony outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. Lancet 392:1519–1529PubMed
297.
Rosenstock J, Nino A, Soffer J et al (2020) Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial. Diabetes Care 43:2509–2518PubMedPubMedCentral
298.
Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 385:896–907PubMed
299.
Lam CSP, Ramasundarahettige C, Branch KRH (2022) Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter‑2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE‑O trial. Circulation 145:565–574PubMed
300.
Coskun T, Sloop KW, Loghin C et al (2018) LY3298 176, a novel dual GIP and GLP‑1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab 18:3–14PubMedPubMedCentral
301.
Zhao F, Zhou Q, Cong Z et al (2022) Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP‑1 or glucagon receptors. Nat Commun 13:1057PubMedPubMedCentral
302.
Frias JP, Nauck MA, Van Joanna DOJ et al (2020) Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide‑1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab 22:938–946PubMedPubMedCentral
303.
Nauck MA, Wefers J, Meier JJ (2021) Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol 9:525–544PubMed
304.
Rosenstock J, Wysham C, Frías JP et al (2021) Efficacy and safety of a novel dual GIP and GLP‑1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398:143–155PubMed
305.
Frías JP, Davies MJ, Rosenstock J (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385:503–515PubMed
306.
Hartman ML, Sanyal AJ, Loomba R et al (2020) Effects of novel dual GIP and GLP‑1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43:1352–1355PubMedPubMedCentral
307.
Wilson JM, Nikooienejad A, Robins DA et al (2020) The dual glucose-dependent insulinotropic peptide andglucagon-like peptide‑1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab 22:2451–2459PubMedPubMedCentral
308.
Sattar N, McGuire DK, Pavo I (2022) Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 28:591–598PubMedPubMedCentral
309.
Karagiannis T, Avgerinos I, Liakos A et al (2022) Management of type 2 diabetes with the dual GIP/GLP‑1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 17:1–11
310.
Dutta D, Surana V, Singla R et al (2021) Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP‑1 receptor agonist in the management of type‑2 diabetes: A Cochrane meta-analysis. Indian J Endocrinol Metab 25:475–489PubMed
311.
Vilsbøll T, Bain SC, Leiter LA et al (2018) Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 20:889–897PubMedPubMedCentral
312.
Sattar N, Lee MMY, Kristensen S et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP‑1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9:653–662PubMed
313.
Bethel MA, Diaz R, Castellana N (2021) HbA1c change and diabetic retinopathy during GLP‑1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care 44:290–296PubMed
314.
Wang F, Mao Y, Wang H et al (2022) Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Clin Drug Investig 42:17–28PubMed
315.
Gaborit B, Julla JB, Besbes S et al (2020) Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the angiosafe type 2 diabetes study. J Clin Endocrinol Metab 105:dgz69PubMed
316.
Monami M, Nreu B, Scatena A et al (2017) Safety issues with glucagon-like peptide‑1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab 19:1233–1241PubMed
317.
Abd El Aziz M, Cahyadi O, Meier JJ et al (2020) Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab 22:699–704PubMed
318.
Cao C, Yang S, Zhou Z (2019) GLP‑1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine 66:157–165PubMed
319.
Azoulay L, Filion KB, Platt RW et al (2016) Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med 176:1464–1473PubMed
320.
Wang T, Wang F, Gou Z et al (2015) Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324 515 patients from observational studies. Diabetes Obes Metab 17:32–41PubMed
321.
Ueda P, Wintzell V, Melbye M et al (2021) Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Diabetologia 64:2204–2214PubMedPubMedCentral
322.
Piccoli GF, Mesquita LA, Stein C et al (2021) Do GLP‑1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis. J Clin Endocrinol Metab 106:912–921PubMed
323.
Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113–1124PubMed
324.
Gastaldelli A, Cusi K, Fernández Landó L (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS‑3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS‑3 trial. Lancet Diabetes Endocrinol 10:393–406PubMed
325.
Mantsiou C, Karagiannis T, Kakotrichi P et al (2020) Glucagon-like peptide‑1 receptor agonists and sodium-glucose co-transporter‑2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 22:1857–1868PubMed
326.
Wright AK, Carr MJ, Kontopantelis E (2022) Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP‑1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care 45:909–918PubMed
327.
Russell-Jones D, Pouwer F, Khunti K (2018) Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab 20:488–496PubMed
328.
Landgraf R, Aberle J (2021) Hundert Jahre – Insulin bleibt aktuell und notwendig. Diabetologie 16:1–13
329.
Retnakaran R, Zinman B (2022) The ongoing evolution of basal insulin therapy over 100 years and its promise for the future. Diabetes Obes Metab 24(Suppl. 1):17–26PubMed
330.
Bolli GB, Porcellati F, Lucidi P et al (2022) One-hundred years evolution of prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs. Metabolism 126:154935PubMed
331.
Marso SP, McGuire DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377:723–732PubMedPubMedCentral
332.
Pieber TR, Marso SP, McGuire DK et al (2018) DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 61:58–65PubMed
333.
Lau IT, Lee KF, So WY et al (2017) Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Diabetes Metab Syndr Obes 10:273–284PubMedPubMedCentral
334.
Ritzel R, Roussel R, Giaccari A et al (2018) Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‑year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab 20:541–548PubMed
335.
Bonadonna RC, Renard E, Cheng A et al (2018) Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important? Diabetes Res Clin Pract 142:19–25PubMed
336.
Blonde L, Bailey T, Sullivan SD et al (2021) Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme. Diabetes Obes Metab 23:1713–1721PubMedPubMedCentral
337.
Linnebjerg H, Lam EC, Seger ME et al (2015) Comparison of the pharmacokinetics and pharmacodynamics of LY2963 016 insulin glargine and EU and US-approved versions of lantus insulin glargine in healthy subjects: Three randomized euglycemic clamp studies. Diabetes Care 38:2226–2233PubMed
338.
Rosenstock J, Hollander P, Bhargava A et al (2015) Similar efficacy and safety of LY2963 016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, doubleblind controlled trial (ELEMENT 2 study). Diabetes Obes Metabol 17:734–741
339.
Yamada T, Kamata R, Ishinohachi K et al (2018) Biosimilar vs originator insulins: Systematic review and meta-analysis. Diabetes Obes Metab 20:1787–1792PubMed
340.
But A, De Bruin ML, Bazelier MT et al (2017) Cancer risk among insulin users: Comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia 60:1691–1703PubMedPubMedCentral
341.
Maiorino MI, Chiodini P, Bellastella G et al (2017) Insulin and glucagon-like peptide1 receptor agonist combination therapy in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Care 40:614–624PubMed
342.
Guja C, Frías JP, Somogyi A et al (2018) Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‑7 randomized study. Diabetes Obes Metab 20:1602–1161PubMedPubMedCentral
343.
Rodbard HW, Lingvay I, Reed J et al (2018) Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): A randomized, controlled trial. J Clin Endocrinol Metab 103:2291–2301PubMedPubMedCentral
344.
Huthmacher JA, Meier JJ, Nauck MA (2020) Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a metaanalysis. Diabetes Care 43:2303–2312PubMed
345.
Rosenstock J, Emral R, Sauque-Reyna L et al (2021) Advancing therapy in suboptimally controlled basal insulin–treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIasp 30 in the solimix randomized controlled trial. Diabetes Care 44:2361–2370PubMedPubMedCentral
346.
Gentile S, Fusco A, Colarusso S et al (2018) A randomized, openlabel, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin U‑100 versus concentrated lispro insulin U‑200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence. Expert Opin Drug Saf 17:445–450PubMed
347.
Heise T, Hövelmann U, Brøndsted L et al (2015) Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 17:682–688PubMedPubMedCentral
348.
Bowering K, Case C, Harvey J et al (2017) Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: The ONSET 2 trial. Diabetes Care 40:951–957PubMed
349.
Heise T, Piras de Oliveira C, Juneja R et al (2022) What is the value of faster acting prandial insulin? Focus on ultra-rapid lispro. Diabetes Obes Metab: 1–13
350.
Leohr J, Kazda C, Liu R et al (2022) Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study. Diabetes Obes Metab 24:187–195PubMed
351.
Tan J, Wang Y, Liu S et al (2021) Long-acting metformin vs. metformin immediate release in patients with type 2 diabetes: a systematic review. Front Pharmacol 12:669814PubMedPubMedCentral
352.
Aberle J, Lautenbach A, Meyhöfer S et al (2021) Adipositas und Diabetes. Diabetologe 16(Suppl. 02):S290–S298
353.
Mengden T, Weisser B (2021) Therapieüberwachung bei arterieller Hypertonie. Dtsch Arztebl 118:473–478
354.
Banegas JR, Ruilope LM, de la Sierra A et al (2018) Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 378:1509–1520PubMed
Metadaten
Titel
Therapie des Typ-2-Diabetes
verfasst von
Prof. Dr. med. Rüdiger Landgraf
Jens Aberle
Andreas L. Birkenfeld
Baptist Gallwitz
Monika Kellerer
Harald H. Klein
Dirk Müller-Wieland
Michael A. Nauck
Tobias Wiesner
Erhard Siegel
Publikationsdatum
27.04.2023
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 5/2023
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-023-01047-y

Weitere Artikel der Ausgabe 5/2023

Die Diabetologie 5/2023 Zur Ausgabe

Journal Club

Bariatrische Chirurgie vs. Lebensstilintervention bei Personen mit Steatohepatitis

Leitthema

Selbstmanagement – eine unterschätzte Ressource in der Versorgung von Menschen mit Typ-2-Diabetes

Leitthema

Versorgungsqualität in den Disease-Management-Programmen für Typ-2- und Typ‑1‑Diabetes

Leitthema

Versorgungsauftrag der diabetologischen Schwerpunktpraxen in Deutschland

Mitteilungen des BDE

Mitteilungen des BDE

DDG Praxisempfehlungen

DDG Praxisempfehlungen: Diabetes mellitus und Herz

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft. 

Zu den Praxisempfehlungen
Bildnachweise